ANDA 65453, held by Fresenius Kabi USA. Vancomycin Hydrochloride.
As of Nov 16, 2026, ANDA 65453 (Vancomycin Hydrochloride), held by Fresenius Kabi USA, was first approved by FDA on Jun 18, 2012, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 18, 2012 | Original application | Approved | None posted |
| Vancomycin HydrochlorideEQ 125MG BASE · capsule;oral | Vancomycin Hydrochloride | Discontinued |
| Vancomycin HydrochlorideEQ 250MG BASE · capsule;oral | Vancomycin Hydrochloride | Discontinued |
| Jul 31, 2013 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jun 18, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters